Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Operating expenses:    
Research and development $ 1,488,839 $ 862,420
General and administrative 4,378,897 1,771,796
Depreciation and amortization 7,935 2,903
Total operating expenses 5,875,671 2,637,119
Loss from operations (5,875,671) (2,637,119)
Other income (expense):    
Interest income 6,123 85
Loss before income taxes (5,869,548) (2,637,034)
Income taxes (benefit) 0 0
Net loss (5,869,548) (2,637,034)
Preferred stock dividend (10,541) (305,046)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (5,880,089) $ (2,942,080)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.33) $ (0.25)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 17,848,238 11,977,778